Overview of Global Development Structure

Centered on its global headquarters in Japan, SHIONOGI is advancing global development in collaboration with SHIONOGI Group companies in the United States, Europe, and China. Japanese expatriates are also stationed at each Group company, where many development team members are playing active roles.

In 2023, SHIONOGI strengthened its global capabilities to address the threat of infectious diseases and prepare for future pandemics by bringing Qpex Biopharma, Inc., a company with strengths in infectious diseases and a focus on the discovery and development of novel antibacterial agents targeting antimicrobial-resistant bacteria, into the Group.

In 2026, SHIONOGI also made Shionogi-Apnimed Sleep Science, LLC (“SASS”), which had been established to provide promising solutions that address unmet needs in the field of sleep disorders, a wholly owned subsidiary.

Full development function is in New Jersey, U.S and plays a key role in consultations with the U.S. Food and Drug Administration (FDA).

Headquartered in San Diego, U.S., Qpex has established a development platform for novel antibacterial agents targeting bacteria with antimicrobial resistance (AMR).

Major development functions for Europe are based in London, UK, driving development activities across the European region.

Development function is in Shanghai, China, and it plays a key role in development activities in the China region within global development.